Advanced BioScience Laboratories, Inc. (ABL) has been selected by PATH, a nonprofit global health organization, for the development and production of a novel Shigella vaccine candidate. ABL will develop a scalable production process under cGMP to produce toxicology and Phase I clinical supply at its facility in Rockville, MD.   The vaccine candidate is based on an IpaB/IpaD fusion protein technology developed by Dr. Wendy Picking at the Department of Microbiology and Molecular Genetics, Oklahoma...